Mon. 3 Jun 2024, 8:19am ET
Benzinga
Biotech, News, Health Care, General
- Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.
- Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases.